Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.
The new cure could be a boon to poorer nations.
The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.
Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.